News >

CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings

Caroline Seymour
Published: Wednesday, Feb 27, 2019

Joseph F. Stilwill, MD

Joseph F. Stilwill, MD

All 3 FDA-approved CDK4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)—show a consistent progression-free survival (PFS) advantage for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer, irrespective of endocrine therapy use, line of therapy, menopausal status, and clinical and pathologic features.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication